The Effect of Transdermal Oestrogen on Bone, Calcium-Regulating Hormones and Liver in Postmenopausal Women

Clin Endocrinol (Oxf). 1986 Nov;25(5):543-7. doi: 10.1111/j.1365-2265.1986.tb03607.x.


Transdermal oestradiol, 100 micrograms/d, was used to treat 11 women suffering from postmenopausal symptoms. After 3 weeks therapy there was a significant rise in the plasma oestradiol into the premenopausal range and a significant fall in plasma FSH level and symptom score. Bone resorption, assessed by urinary excretion of calcium and hydroxyproline, decreased significantly while plasma alkaline phosphatase activity remained constant. There was a significant fall in plasma calcium and phosphate but the plasma concentrations of PTH, calcitonin and calcitriol and the urinary excretion of cAMP were unchanged. Plasma levels of vitamin D binding protein, albumin and globulin were unaltered, and blood pressure did not rise. These effects were similar to those found in postmenopausal women with oral ethinyloestradiol, 30 micrograms/d, (Selby et al., 1985), apart from those on plasma vitamin D binding protein, total calcitriol, albumin, globulin, tubular reabsorption of phosphate and blood pressure, changes which probably arise from a direct action of oral oestrogen on the liver.

MeSH terms

  • Administration, Cutaneous
  • Bone Resorption / drug effects
  • Bone and Bones / drug effects*
  • Calcitonin / blood
  • Calcium / blood
  • Estradiol / administration & dosage*
  • Estradiol / blood
  • Estradiol / therapeutic use
  • Female
  • Follicle Stimulating Hormone / blood
  • Humans
  • Liver / drug effects*
  • Menopause*
  • Middle Aged
  • Osteoporosis / blood
  • Osteoporosis / drug therapy*
  • Phosphates / blood


  • Phosphates
  • Estradiol
  • Follicle Stimulating Hormone
  • Calcitonin
  • Calcium